Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of immune deficiency patients treated with subcutaneous immunoglobulin (Hizentra) on weekly and biweekly schedules
2015-004977-34Phase 4
- Sponsor
- CSL Limited
- Start
- Feb 2016
- Countries
- 1
01
Overview
Phase 4, open-label trial of polyvalent human immunoglobulin in Immunogenetic disorder (2 arms), sponsored by CSL Limited. Primary endpoint: Annualized rate of adverse events (local and systemic).
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2015-004977-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004977-34.